Importantly, MOS treatment reduced the overexpression of tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6) in the brains of AD mice, effectively alleviated neuroinflammation and oxidative damage in the brains of AD mice [59]. Here, IL6 is linked to Alzheimer disease.